Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

28.98 +0.41 (+1.44%)
Streaming Delayed Price Updated: 10:13 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 103,563
Open 28.50
Bid (Size) 28.86 (400)
Ask (Size) 29.14 (500)
Prev. Close 28.57
Today's Range 28.45 - 29.08
52wk Range 25.52 - 40.93
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price
Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock. 
Via Chartmill
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud

Performance

YTD
-16.8%
-16.8%
1 Month
+6.2%
+6.2%
3 Month
-18.5%
-18.5%
6 Month
-3.3%
-3.3%
1 Year
-12.3%
-12.3%

More News

Read More
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?
Via Stocktwits
Earnings Scheduled For August 5, 2025
Via Benzinga
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup
Via Chartmill
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity
Via Chartmill
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study
Via Stocktwits
Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock
Via Chartmill
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Via Chartmill
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup
Via Chartmill
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 28.98
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 11/03/25 10:13 AM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.65B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.